Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03824483 · ClinicalTrials.gov registry record · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
A Phase 2 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL), sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
- 8
- Study locations
NCT03824483 is a Phase 2 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL) that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 230 participants, above the 184-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (25% higher). The trial reports 8 study locations across 4 states.
The verdict
NCT03824483, a Phase 2 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL), is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for CLL and/or SLL.
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Obinutuzumab
- DRUG Venetoclax
Study Locations (8)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering at Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
Illinois
- Northwestern University - Evanston
Massachusetts
- Massachusetts General Hospital (Data Collection and Specimen Analysis) - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2019-02-22 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03824483
The ClinicalTrials.gov registry entry for NCT03824483 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 184-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (25% higher). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Lymphocytic Leukemia (CLL) appearing as the primary indexed condition, and to 3 interventions - of which Zanubrutinib is the first listed.
NCT03824483 reports 8 study locations spanning 4 distinct geographic areas - top geographies include New York, New Jersey, Illinois.
Frequently Asked Questions
What is clinical trial NCT03824483 about?
NCT03824483 is a clinical study titled "Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)". The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for CLL and/or SLL.
What is the current status of trial NCT03824483?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2019-02-22. Estimated completion is 2027-02.
What conditions does trial NCT03824483 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL).
What interventions are being tested in trial NCT03824483?
The interventions under investigation include: Zanubrutinib (DRUG), Obinutuzumab (DRUG), Venetoclax (DRUG).
Who is sponsoring clinical trial NCT03824483?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03824483 being conducted?
This trial has 8 study locations across Illinois, Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia (CLL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
RECRUITING · Phase 2
-
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
RECRUITING · Phase 2
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
ACTIVE NOT RECRUITING · Phase 2
-
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
ACTIVE NOT RECRUITING · Phase 2
-
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Chronic Lymphocytic Leukemia (CLL)
All registered trials for this condition
Small Lymphocytic Leukemia (SLL)
All registered trials for this condition
Illinois
All trials with a study site in Illinois
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.